Compare LITS & NUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LITS | NUR |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 25.2M |
| IPO Year | 2003 | 2016 |
| Metric | LITS | NUR |
|---|---|---|
| Price | $1.11 | $1.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 276.9K | ★ 7.0M |
| Earning Date | 05-19-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $1.38 |
| 52 Week High | $3.03 | $7.72 |
| Indicator | LITS | NUR |
|---|---|---|
| Relative Strength Index (RSI) | 58.18 | 36.55 |
| Support Level | $0.97 | N/A |
| Resistance Level | $1.11 | $7.72 |
| Average True Range (ATR) | 0.07 | 0.98 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 54.95 | 5.11 |
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.